Molecular cross-talk between the TRAIL and interferon signaling pathways

Chandan Kumar-Sinha1, Sooryanarayana Varambally, Arun Sreekumar

  • 1Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interferon-beta synergistically enhance breast cancer cell death. This study reveals cross-talk between TRAIL and interferon signaling pathways, offering new therapeutic insights.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) induces apoptosis in cancer cells, showing therapeutic potential.
  • The full scope of TRAIL-mediated signaling extends beyond simple caspase activation.
  • Understanding TRAIL's complex signaling is crucial for developing effective anti-cancer therapies.

Purpose of the Study:

  • To investigate TRAIL-mediated gene expression in breast carcinoma cells using DNA microarrays.
  • To elucidate the molecular interactions between TRAIL and interferon signaling pathways.
  • To explore the combined therapeutic potential of TRAIL and interferon-beta in breast cancer.

Main Methods:

  • DNA microarrays were employed to profile gene expression changes induced by TRAIL in breast cancer cells.
  • Analysis focused on identifying primary response genes and interferon-related signaling pathways.
  • In vitro experiments combined TRAIL and interferon-beta to assess synergistic effects on apoptosis and caspase activation.

Main Results:

  • TRAIL induced known NF-kappaB-dependent genes (e.g., cIAP2, A20, E-selectin) and a significant cohort of interferon-signaling pathway genes.
  • Evidence of molecular cross-talk was observed, including interferon-mediated upregulation of TRAIL and TRAIL-mediated induction of interferon-beta.
  • Combined treatment with TRAIL and interferon-beta synergistically enhanced apoptosis and caspase activation in breast cancer cells.

Conclusions:

  • TRAIL signaling in breast cancer cells involves intricate cross-talk with the interferon pathway.
  • The combination of TRAIL and interferon-beta demonstrates synergistic anti-tumor activity.
  • These findings highlight novel therapeutic strategies by combining TRAIL and interferon-based treatments for breast cancer.

Related Concept Videos

Intracellular Signaling Cascades01:24

Intracellular Signaling Cascades

Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
Intracellular Signaling Cascades01:24

Intracellular Signaling Cascades

Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...